FDA drug-testing rules rewritten without public input, fast-tracked for industry
H.R. 2821 — FDA Modernization Act 3.0 · Filed by Buddy Carter (R-GA) · 41 cosponsors · Introduced Apr 10, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the FDA to publish a rule within one year replacing all references to 'animal tests' with 'nonclinical tests' in drug approval regulations, implementing a 2023 law that broadened what counts as acceptable testing data. The rule becomes effective immediately without the FDA having to justify the change through normal public comment procedures.
Why we flagged it
The bill's substantive goal—replacing animal-testing language with nonclinical-testing language—is a modernization aligned with 2023 law. However, the operative mechanism is a procedural bypass: it exempts the FDA from demonstrating 'good cause' for an interim final rule and makes it effective immediately, circumventing the Administrative Procedure Act's notice-and-comment requirement.
What the text implies
- The 'immediately effective' interim final rule (bypassing APA notice-and-comment) means the public and scientific community cannot formally challenge the adequacy of nonclinical testing standards before they take effect, reducing democratic input on drug-safety standards.
- The bill references a 2023 law (Consolidated Appropriations Act, 2023) that already amended section 505 of the FDCA; this bill operationalizes that change but does so via procedural shortcut rather than transparent rulemaking.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies; biotechnology firms; contract research organizations (CROs) specializing in nonclinical testing